Aurora A kinase activation contributes to the fibrotic phenotype in Systemic Sclerosis through primary cilia shortening

This study demonstrates that aberrant activation of the AURKA/HDAC6 axis drives primary cilia shortening and fibroblast activation in Systemic Sclerosis, identifying AURKA as a promising therapeutic target to reverse the fibrotic phenotype.

The Gist

The Big Picture: A Broken Antenna and a Stuck Construction Crew

Imagine your body's cells are like construction workers building a house. In a healthy body, these workers (called fibroblasts) know exactly when to build and when to stop. They have a special "sensor" on top of their heads called a primary cilium. Think of this cilium as a cellular antenna.

• Healthy Antenna: It's long and fully extended. It picks up signals from the environment telling the cell, "Everything is fine, keep things as they are."
• The Problem in Systemic Sclerosis (SSc): In patients with this disease, the construction workers go haywire. They start building too much "concrete" (collagen), causing the skin and organs to become hard and stiff (fibrosis). The researchers found that in these sick cells, the antenna is chopped short. Because the antenna is short, the cell can't hear the "stop" signals and keeps building.

The big question was: Why is the antenna so short, and can we fix it?

---

The Investigation: Who Cut the Antenna?

The scientists suspected that a famous "boss" molecule called TGF-β (which usually tells cells to build) was the culprit. They thought TGF-β was constantly shouting, "Build! Build!" and cutting the antennas short.

The Twist: They tested this by blocking TGF-β.

• Result: Even when they blocked TGF-β, the sick cells still had short antennas.
• Conclusion: TGF-β isn't the one holding the scissors in this specific case. The short antenna is a permanent feature of the sick cells, not just a reaction to a signal.

The Real Culprit: The "Aurora A" Scissors

The researchers dug deeper and found the real pair of scissors: a protein called Aurora A kinase (AURKA).

• The Analogy: Imagine AURKA is a hyper-active gardener whose job is to trim the antenna. In healthy cells, this gardener only trims when the cell is about to divide (like a seasonal prune).
• In SSc Cells: The gardener has gone crazy. He is constantly trimming the antenna, keeping it short no matter what.
• The Mechanism: This crazy gardener activates another tool called HDAC6, which literally strips the "glue" (acetylation) off the antenna's microtubules, causing it to fall apart.

The Solution: Putting the Scissors Down

The team decided to test if they could stop the crazy gardener. They used a drug (an inhibitor) to block AURKA.

• The Result: When they stopped the gardener, the antennas on the sick cells grew back to normal length.
• The Bonus: Once the antennas grew back, the cells stopped acting like crazy construction workers. They stopped making so much "concrete" (collagen) and stopped contracting (squeezing) so hard.
• Selectivity: Crucially, this drug only fixed the sick cells. It didn't mess with the healthy cells, which already had normal antennas.

The Root Cause: The Missing "Caveolin-1"

Why was the gardener crazy in the first place? The researchers found a missing piece of the puzzle called Caveolin-1 (CAV1).

• The Analogy: Think of Caveolin-1 as the security guard who usually tells the gardener, "Hey, stop trimming! The antenna is fine."
• In SSc: The security guard is missing (low levels of Caveolin-1). Without the guard, the gardener (AURKA) runs wild, chopping the antenna and causing the cell to go into overdrive.

Why This Matters

This study is a game-changer for two reasons:

1. It explains the "Why": We now know that short antennas aren't just a symptom; they are a cause of the disease. The short antenna keeps the cell in "build mode."
2. It offers a new treatment: Since we have drugs that can block AURKA (some are already being tested for cancer), this study suggests we could repurpose these drugs to treat Systemic Sclerosis. By stopping the "crazy gardener," we can let the antennas grow back, calm the cells down, and potentially reverse the hardening of the skin and organs.

Summary in One Sentence

The researchers discovered that in Systemic Sclerosis, a missing security guard allows a hyper-active "gardener" to chop off the cells' sensory antennas, causing them to over-build scar tissue; stopping the gardener allows the antennas to grow back and the cells to return to normal.

Technical Summary

1. Problem Statement

Systemic Sclerosis (SSc) is a severe autoimmune disease characterized by progressive fibrosis driven by the activation of fibroblasts into myofibroblasts. A hallmark of SSc fibroblasts is the presence of constitutively shortened primary cilia, which are critical signaling hubs for profibrotic pathways (e.g., Hedgehog, TGFβ, Wnt). While the correlation between short cilia and fibrosis is established, the molecular mechanisms driving this ciliary phenotype in SSc remain unclear. Specifically, it is unknown whether this shortening is driven by canonical TGFβ signaling or other upstream regulators, and whether reversing this phenotype can mitigate fibrotic activation.

2. Methodology

The study utilized a combination of primary human dermal fibroblasts, immortalized cell lines, and pharmacological/genetic interventions:

• Cell Models: Primary fibroblasts from healthy controls (HC), diffuse cutaneous SSc (dcSSc) patients, and Very Early Diagnosis of Systemic Sclerosis (VEDOSS) patients. Additionally, a model of SSc was created by silencing Caveolin-1 (CAV1) in healthy fibroblasts (shCAV1), as CAV1 loss is a known feature of SSc.
• Pharmacological Inhibitors:
  • AURKA inhibitor: MLN8054 (targets Aurora A kinase).
  • HDAC6 inhibitor: Tubacin (targets Histone Deacetylase 6).
  • ROCK2 inhibitor: KD025 (targets Rho-associated kinase 2).
  • TGFβRI inhibitor: SD208 (blocks canonical TGFβ signaling).
• Genetic Manipulation:
  • siRNA: Knockdown of SMAD3 to inhibit canonical TGFβ signaling.
  • shRNA: Lentiviral knockdown of CAV1.
• Assays:
  • Immunofluorescence: Quantification of primary cilia length and incidence (using Acetylated-α-Tubulin and Ki67 markers).
  • Western Blotting: Analysis of protein levels (p-AURKA, p-MLC2, p-SMAD3, Ac-α-tubulin, CAV1).
  • qPCR: Measurement of profibrotic markers (ACTA2, CCN2, COL1A1, COL1A2, FN1).
  • Collagen Gel Contraction Assay: Functional assessment of fibroblast contractility.

3. Key Contributions & Results

A. The Short Cilia Phenotype is Stable and Independent of Canonical TGFβ Signaling

• SSc and VEDOSS fibroblasts exhibit significantly shorter primary cilia compared to healthy controls, a phenotype that persists through serial passaging and immortalization.
• TGFβ1 Treatment: While exogenous TGFβ1 induces reversible cilia shortening in healthy cells, the constitutive shortening in SSc cells is not maintained by canonical TGFβ/SMAD3 signaling. Inhibiting SMAD3 or blocking TGFβRI (SD208) failed to restore cilia length in SSc fibroblasts to healthy levels.

B. Mechanism of TGFβ-Induced Shortening: Non-Canonical Rho/ROCK2 Pathway

• TGFβ1 induces rapid cilia shortening in both healthy and SSc cells via a non-canonical pathway.
• Knockdown of SMAD3 did not prevent TGFβ-induced shortening.
• However, inhibition of ROCK2 (KD025) blocked TGFβ-induced cilia shortening, indicating that TGFβ acts through the RhoA/ROCK2 axis to drive ciliary disassembly.

C. The Core Driver: Aberrant AURKA/HDAC6 Axis in SSc

• The constitutive short cilia phenotype in SSc is driven by hyperactivation of Aurora A kinase (AURKA).
• AURKA phosphorylates and activates HDAC6, leading to the deacetylation of α-tubulin and subsequent ciliary disassembly.
• Intervention: Treatment with the AURKA inhibitor (MLN8054) or HDAC6 inhibitor (Tubacin) selectively elongated cilia in SSc fibroblasts (restoring them to healthy lengths) without affecting healthy control cells.
• Notably, TGFβ1-induced shortening is independent of AURKA/HDAC6, suggesting two distinct mechanisms: a basal AURKA-driven defect in SSc and an acute ROCK2-driven response to TGFβ.

D. CAV1 Downregulation as the Upstream Trigger

• CAV1 Silencing: Knocking down CAV1 in healthy fibroblasts recapitulated the SSc phenotype: constitutive cilia shortening and increased contractility.
• Rescue: In shCAV1 cells, AURKA inhibition (MLN8054) successfully rescued cilia length and reduced fibrotic markers.
• This suggests that loss of CAV1 is an upstream event that triggers aberrant AURKA activation, leading to ciliary shortening and fibroblast activation.

E. Functional Impact on Fibrosis

• Inhibiting AURKA or HDAC6 in SSc fibroblasts (and shCAV1 models) resulted in:
  • Reduced expression of profibrotic markers (ACTA2, CCN2, COL1A1).
  • Abrogation of excessive cell contractility in collagen gels.
• This establishes a direct mechanistic link: Short Cilia $\rightarrow$ AURKA/HDAC6 Activation $\rightarrow$ Fibroblast Activation.

4. Significance and Conclusion

• Mechanistic Insight: The study identifies a specific molecular axis (CAV1 loss $\rightarrow$ AURKA hyperactivation $\rightarrow$ HDAC6 activation $\rightarrow$ Cilia shortening) responsible for the fibrotic phenotype in SSc. It distinguishes between the basal constitutive shortening (AURKA-driven) and acute TGFβ-induced shortening (ROCK2-driven).
• Therapeutic Potential: The findings suggest that AURKA inhibitors (some of which are in clinical trials for oncology) could be repurposed to treat SSc-associated fibrosis. By restoring primary cilia length, these inhibitors can suppress myofibroblast activation and contractility.
• Selectivity: Crucially, AURKA inhibition selectively targets the diseased (SSC) phenotype without altering the cilia length of healthy fibroblasts, suggesting a favorable safety profile for non-oncological use.
• Early Intervention: Since the short cilia phenotype is present in VEDOSS patients (very early disease), targeting this pathway could potentially halt or reverse fibrosis before extensive tissue remodeling occurs.